Advanced search
Publication Cover
Journal of Chemotherapy Volume 35, 2023 - Issue 2
Submit an article Journal homepage
152
Views
11
CrossRef citations to date
0
Altmetric
Brief Communication

Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials

Andrea MessoriHTA Unit, Regione Toscana, Firenze, ItalyCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5829-107X
ORCID Icon &
Sabrina TrippoliHTA Unit, Regione Toscana, Firenze, ItalyORCID Iconhttps://orcid.org/0000-0002-5762-1807
ORCID Icon
Pages 158-162 | Received 23 Jan 2022, Accepted 28 Mar 2022, Published online: 12 Apr 2022

References

  • Pezzicoli G, Rizzo M, Perrone M, et al. A glimpse in the future of malignant mesothelioma treatment. Front Pharmacol. 2021;12:809337 PMID: 34975505; PMCID: PMC8714955.
  • Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;S0923-7534(22):00083–00087. Epub ahead of print. PMID: 35124183.
  • Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414.
  • Yap TA, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021;9(6):613–621. Epub 2021 Apr 6. PMID: 33836153.
  • Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213–1223. PMID: 32888453.
  • Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17(4):786–802.
  • Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111 PMID: 34074267; PMCID: PMC8168323.
  • Messori A. Synthetizing published evidence on survival by reconstruction of Patient-Level data and generation of a Multi-Trial Kaplan-Meier Curve. Cureus. 2021;13(11):e19422 PMID: 34786276; PMCID: PMC8578838.
  • Cancanelli L, Rivano M, Di Spazio L, et al. Efficacy of immune checkpoint inhibitors in patients with mismatch Repair-Deficient or microsatellite Instability-High metastatic colorectal cancer: Analysis of three Phase-II Trials. Cureus. 2021;13(11):e19893 PMID: 34966607; PMCID: PMC8710086., url https://pubmed.ncbi.nlm.nih.gov/34966607/
  • Messori A, Rivano M, Mengato D, et al. A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukaemia. Leukemia Lymphoma. 2022; (in press). Available from: at https://www.tandfonline.com/eprint/TWPDKPRVUQV6YKXDHKDX/full?target=10.1080/10428194.2021.2022141 https://pubmed.ncbi.nlm.nih.gov/34969325/
  • Di Spazio L, Rivano M, Cancanelli L, et al. The degree of programmed Death-Ligand 1 (PD-L1) positivity as a determinant of outcomes in metastatic Triple-Negative breast cancer treated with First-Line immune checkpoint Inhibitors. Cureus. 2022;14(1):e21065 url https://assets.cureus.com/uploads/review_article/pdf/82270/20220110-16971-mzer54.pdf
  • Trippoli S, Di Spazio L, Chiumente M, et al. Medical therapy, radiofrequency ablation, or cryoballoon ablation as First-Line treatment for paroxysmal atrial fibrillation: Interpreting efficacy through the shiny Method. Cureus. 2022;14(2):e22645 url https://assets.cureus.com/uploads/review_article/pdf/87681/20220227-20768-138ikup.pdf
  • Messori A, Trippoli S. Current first-line treatments for inoperable mesothelioma: a PubMed search to select novel treatments proposed from 2015 to 2021 (preprint). Open Science Framework published 2022 Mar 6. https://osf.io/erxz7/.
  • R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2021. https://www.R-project.org
  • Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. Epub 2021 Jan 21. Erratum in: Lancet. 2021 Feb 20;397(10275):670. PMID: 33485464.
  • Correale P, Pentimalli F, Nardone V, et al. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? Lancet onc correale P, pentimalli F, nardone V, giordano A, mutti L. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? Lancet Oncol. 2022;23(1):e13. PMID: 34973223.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.